专栏咏竹坊

Medical Device Maker Broncus Gets Financial Breathing Room from IPO

Investors are betting company can quickly ramp up sales for its core pulmonary devices, most of which have been approved or are near approval in China, the U.S. and Europe

This article only represents the author's own views.

Seven months.

That’s how much time medical device maker Broncus Holding Corp. (2216.HK) appears to have gained for itself from its new Hong Kong IPO that raised HK$1.55 billion ($200 million) last Friday. Based on its IPO prospectus filed back in May, the company looks like a classic underachiever just waiting to blossom when the world discovers its devices used to detect and treat lung diseases, including lung cancer.

您已阅读8%(473字),剩余92%(5536字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

咏竹坊

咏竹坊(官网链接)提供在香港和美国上市的manbetx3.0 企业相关新闻,重点关注中小企业和筹备上市的公司。

Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.

相关文章

相关话题

设置字号×
最小
较小
默认
较大
最大
分享×